Emerging molecular targets and therapy for cholangiocarcinoma.
MetadataShow full item record
Cholangiocarcinoma (CCA) is a rare cancer arising from the biliary tree with a poor prognosis and limited therapeutic options. Recent large scale molecular characterisation studies have identified recurrent genetic alterations in CCA which may be amenable to therapeutic targeting. In this review we explore the genomic landscape of CCA and examine results from trials of molecularly targeted agents and immunotherapy in this disease. Challenges in CCA diagnosis, treatment and trial design are discussed and we reflect on future directions which may lead to improved outcomes for CCA patients.
Signal Transduction & Molecular Pharmacology
License start date
World journal of gastrointestinal oncology, 2017, 9 (7), pp. 268 - 280